Effects of body mass index on the lipid profile and biomarkers of inflammation and a fibrinolytic and Prothrombotic state

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 6, 2015, Pages 610-617

  Orenes Piñero, Esteban ^a   Pineda, Javier ^b   Roldán, Vanessa ^c   Hernández Romero, Diana ^a   Marco, Pascual ^b   Tello Montoliu, Antonio ^a   Sogorb, Francisco ^b   Valdés, Mariano ^a   Lip, Gregory Y H ^d   Marín, Francisco ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Fibrinolysis; Inflammation; Lipid profile; Obesity; Prothrombotic state

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; D DIMER; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR ANTIGEN 1; PROTHROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; AUTACOID; LIPID;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; FOLLOW UP; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; THROMBOSIS;

ADULT; AGED; BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOGEN; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INFLAMMATION; INFLAMMATION MEDIATORS; LIPIDS; MALE; MIDDLE AGED; PROGNOSIS; THROMBOSIS;

EID: 84931060134     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.26161     Document Type: Article

References (48)

1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser, 2000; 894: 1-253.
2. Abate N: Obesity as a risk factor for cardiovascular disease. Am J Med, 1999; 107: 12S-3.
3. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr: Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med, 1999; 341: 1097-1105.
4. Eckel RH, Krauss RM: American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation, 1998; 97: 2099-2100.
5. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institues of Health Organization; 1998.
6. James PT, Leach R, Kalamara E, Shayeghi M: The worldwide obesity epidemic. Obes Res, 2001; 9: 228S
7. Shehan MT, Jensen MD: Metabolic complications of obesity: pathological considerations. Med Clin N Am, 2000; 84: 363-385.
8. Wang CS, Sun CF: C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J, 2009; 32: 471-482.
9. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL: Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation, 2004; 109: 6-19.
10. Lee K, Lip GYH: Acute coronary syndromes: Virchow´s triad revisited. Blood Coagul Fibrinolysis, 2003; 14: 1-21.
11. Chobanian A, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA, 2003; 289: 2560-2572.
12. Third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation, 2002; 106: 3143-3421.
13. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 2003; 26 Suppl 1: S5-20.
14. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on standardization of clinical nomenclature. Circulation, 1979; 59: 607-609.
15. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA 3rd, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stöckl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA: Comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012; 380: 2224-2260.
16. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502.
17. Clauss A: Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol, 1957; 17: 237-246.
18. Moccetti T, Malacrida R, Pasotti E, Sessa F, Genoni M, Barlera M, Turazza F, Maggioni AP: Epidemiologic variables and outcome of 1972 young patients with acute myocardial infarction. Data from the GISSI-2 database. The GISSI investigators. Arch Intern Med, 1997; 157: 865-869.
19. Cole JH, Miller JI, Sperling LS, Weintraub WS: Longterm follow-up of coronary artery disease presenting in young adults. J Am Coll Cardiol, 2003; 41: 521-528.
20. Rallidis LS, Lekakis J, Panagiotakos D, Fountoulaki K, Komporozos C, Apostolou T, Rizos I, Kremastinos DT: Long-term prognostic factors of young patients (≤ 35 years) having acute myocardial infarction: the detrimental role of continuation of smoking. Eur J Cardiovasc Prev Rehabil, 2008; 15: 567-571.
21. Prevention of Coronary Heart Disease in Clinical Practice: Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Eur Heart J, 1998; 19: 1434-1503.
22. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined. A consensus document of the Joint European Society of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J, 2000; 21: 1502-1513.
23. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, Hoberg E, Drinkmann A, Bacher F, Grunze M: Regular physical exercise and low-fat diet. Effects of progression on coronary artery disease. Circulation, 1992; 86: 1-11.
24. Keil U, Liese AD, Hense HW, Filipiak B, Döring A, Stieber J, Löwel H: Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J, 1998; 19: 1197-1207.
25. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P: Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation, 1996; 93: 1372-1379.
26. Kitamura A, Iso H, Naito Y, Iida M, Konishi M, Folsom AR, Sato S, Kiyama M, Nakamura M, Sankai T: Highdensity lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation, 1994; 89: 2533-2539.
27. Chen L, Chester M, Kaski J: Clinical factors and angiographic features associated with premature coronary artery disease. Chest, 1995; 108: 364-369.
28. Li JJ, Fang CH: C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses, 2004; 62: 499-506.
29. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB: C-Reactive protein , a sensitive marker of inflammation, predicts future risk of coronary heart disase in initially healthy middleaged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 1999; 99: 237-242.
30. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK: C-Reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J, 2002; 144: 233-238.
31. Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, Koehler E: C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J, 2000; 21: 1000-1008.
32. Hackam DG, Anand SS: Emerging risk factors for atherosclerotic vascular disease. JAMA, 2003; 290: 932-940.
33. Koenig W: Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost, 2003; 89: 601-609.
34. Ernest E, Resch KL: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med, 1993; 118: 956.
35. Folsom A: Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost, 2001; 86: 366-373.
36. Koenig W: Haemostatic risk factors for cardiovascular diseases. Eur Heart J, 1998; 19 (Suppl C): C39-C43.
37. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Masaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framinhgham Heart Study. Circulation, 2008; 112: 743-753.
38. Hoffmeister A, Rothenbacher D, Bäzner U, Fröhlich M, Brenner H, Hombach V, Koenig W: Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol, 2001; 87: 262-266.
39. Maresca G, Di Blasio A, Marchioli R, Di and Minno G: Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol, 1999; 19: 1368-1377.
40. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG: Fibrinolytic factors and the risk of myocardial infaction or sudden death in patients with angina pectoris. Circulation, 1996; 94: 2057-2063.
41. Cesari M, Rossi GP: Plasmingen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol, 1999; 19: 1378-1386.
42. Roldán V, Marín F, Marco P, Martínez JG, Calatayud R, Sogorb F: Hypofibrinolysis in atrial fibrillation. Am Heart J, 1998; 136: 956-960.
43. Marín-Ortuño F, Roldán-Schilling V, Marco-Vera P, Martínez- Martínez JG, Toral-Noguera A, García de Burgos- Rico F, Calatayud-Sendra R, Sogorb-Garri F: Improvement in fibrinolytic function following anticoagulant treatment in chronic rheumatic atrial fibrillation. Rev Esp Cardiol, 1999; 52: 25-30.
44. Roldán V, Marín F, Marco P, Sogorb F: Effect of oral anticoagulation therapy on fibrinolysis parameters in chronic non-rheumatic atrial fibrillation. Haematologica, 2000; 85: 778-780.
45. Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R, Pastore M, Fineschi D, Nami R: Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol, 2000; 75: 227-232.
46. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation CRP Evaluation (PRINCE). JAMA, 2001; 286: 64-70.
47. Szapáry L, Horváth B, Márton Z, Fehér G, Tóth K, Komoly S: Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients. Orv Hetil, 2008; 149: 1117-1123.
48. Tello A, Marín F, Roldán V, García-Herola A, Lorenzo S, Climent VE, de Teresa L, Sogorb F: Effect of maximum dose of atorvastatin on inflammation, thrombogenesis, and fibrinolysis in high-risk patients with ischemic heart disease. Rev Esp Cardiol, 2005; 58: 934-940